SAR439859, an oral selective estrogen receptor (ER) degrader (SERD), in ER+/ HER2-metastatic breast cancer (mBC): Biomarker analyses from a phase I/II study Meeting Abstract
| Authors: | Chandarlapaty, S.; Bardia, A.; Lord, S.; Linden, H.; Pelekanou, V.; Ternes, N.; Ming, J.; Boutet, V.; Boitier, E.; Gosselin, A.; Lee, J. S.; Dos-Santos Bele, W.; Protopopov, A.; Celanovic, M.; Bauchet, A. L.; Campone, M. |
| Abstract Title: | SAR439859, an oral selective estrogen receptor (ER) degrader (SERD), in ER+/ HER2-metastatic breast cancer (mBC): Biomarker analyses from a phase I/II study |
| Meeting Title: | ESMO Virtual Congress 2020 |
| Journal Title: | Annals of Oncology |
| Volume: | 31 |
| Issue: | Suppl. 4 |
| Meeting Dates: | 2020 Sep 19-21/Oct 16-18 |
| Meeting Location: | Virtual |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2020-09-01 |
| Start Page: | S351 |
| Language: | English |
| ACCESSION: | WOS:000573469100277 |
| DOI: | 10.1016/j.annonc.2020.08.379 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 277MO -- Source: Wos |
